Shire is paying $20 million up front to acquire rights to a drug that Parion Sciences has developed as a potential treatment for dry eye disease. The deal calls for Shire (NASDAQ: SHPG) to take the lead on further work on P-321, a compound that Durham, NC-based Parion has tested in early-stage clinical trials. If […]
What Our Clients Say
[ssba_hide]
[testimonials category="Testimonial" random=true limit="1"]
Press Releases and Whitepapers
Industry News & Articles
- Crypto platform Vauld suspends withdrawals, trading and deposits amid financial challenges
- Juragan Material is simplifying Indonesia’s complicated construction supply chain
- PINA offers wealth management for Indonesia’s growing middle- to upper-class
- Despite crypto ban, China’s tech talent rides the global web3 wave
- Without a clear ask, your pitch deck is useless
- Equity crowdfunding appears immune to market volatility, on track for its best year yet
- Tracking Klarna’s plunging valuation
- The 2022 McLaren GT is a fresh take on a classic recipe
Sample Relationships
[logo-carousel id=relationships]
Notables
[logo-carousel id=notables]